SRX Global posts Q3 FY2026 NAV $62.9M, revenue up 27% to $3.4M; Adjusted EBITDA loss improves 35%TradingView·Aug 19 at 10:53 AMSRXH-0.55%
Launch Two Acquisition enters $848,000 working capital note with sponsor Launch Two SponsorPUBT·Aug 18 at 04:16 PMLPBB+0.09%
The 2026 Market Grab-Bag: Cash Cows, Crypto Pivots, and Corporate DelusionsGlobal Report·Aug 18 at 05:12 AMCBOE+0.24%PBR-1.22%
SRXH: Q3 delivered strong sales growth, margin gains, and a highly liquid, debt-free balance sheetQuartr·Aug 13 at 04:47 PMSRXH-0.55%
SRX HealthSolutions Q3 2026 Earnings Call: Complete Transcriptbenzinga_article·Aug 13 at 03:59 PMSRXH-0.55%
SRX Global FY26 Q3 net loss from continuing operations narrows 40% year over year to $4.1 million; net sales rise 27% to $3.4 millionPUBT·Aug 13 at 03:13 PMSRXH-0.55%
Capital Rotates to Fringes: Navigating the Unusual Flows in US Peripheral StocksGlobal Report·Aug 11 at 04:43 AMMTRN+1.16%GME++3.64%
The 2026 Divergence: Cautious Consumers and Aggressive Industrial Infrastructure BetsGlobal Report·Aug 9 at 04:12 AMMPLX-0.17%WDCVV0.00%
Post-Earnings Surges Lift Sprouts and WPP as Diverse Sectors Navigate 2026 Capital ShiftsGlobal Report·Aug 8 at 04:20 AMSATA+0.05%SFM-0.21%
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) | SRXH Stock NewsStockTitan·Aug 3 at 08:00 PMVTGN+1.89%SRXH-0.55%
